Selected Publications
Kaufman, R., Flores, G., Boguslawski, E. A., Kinn-Gurzo, S., Chassé, M., Beddows, I., Adams, M., Stout, M. C., Gaetano, L., Lopez, R., Veluvolu, S., Fuller, A., Kitchen-Goosen, S. M., Tolstyka, Z. P., Gedminas, J. M., & Grohar, P. J. (2026). Mithramycin alters EWS::FLI1 DNA binding and RNA polymerase II processivity to inhibit nascent transcription. Nature communications, 10.1038/s41467-026-69488-9. Advance online publication. https://doi.org/10.1038/s41467-026-69488-9
Tolstyka ZP, Grohar PJ. Exploiting divergent mechanisms of trabectedin for bone tumors. Mol Ther Oncol. 2025 Mar 14;33(2):200959. doi: 10.1016/j.omton.2025.200959. PMID: 40151540; PMCID: PMC11937656.
Jess J, Sorensen KM, Boguslawski EA, Stout MC, Madaj ZB, Caiello BP, Pomaville M, Wilson ER, Kinn-Gurzo SS, Parker CC, Veluvolu SM, Brysgel TV, Kaufman R, Kitchen-Goosen SM, Gedminas JM, Grohar PJ. Cell Context is the third axis of synergy for the combination of ATR inhibition and cisplatin in Ewing sarcoma. Clin Cancer Res. 2024 Mar 20. doi: 10.1158/1078-0432.CCR-23-3063. Epub ahead of print. PMID: 38506712.
Veluvolu SM, Grohar PJ. Importance of pharmacologic considerations in the development of targeted anticancer agents for children. Curr Opin Pediatr. 2023 Feb 1;35(1):91-96. doi: 10.1097/MOP.0000000000001208. Epub 2022 Dec 23. PMID: 36562272.
Shulman DS, Whittle SB, Surdez D, Bailey KM, de Álava E, Yustein JT, Shlien A, Hayashi M, Bishop AJR, Crompton BD, DuBois SG, Shukla N, Leavey PJ, Lessnick SL, Kovar H, Delattre O, Grünewald TGP, Antonescu CR, Roberts RD, Toretsky JA, Tirode F, Gorlick R, Janeway KA, Reed D, Lawlor ER, Grohar PJ. An international working group consensus report for the prioritization of molecular biomarkers for Ewing sarcoma. NPJ Precis Oncol. 2022 Sep 17;6(1):65. doi: 10.1038/s41698-022-00307-2. PMID: 36115869; PMCID: PMC9482616.
Gedminas JM, Kaufman R, Boguslawski EA, Gross AC, Adams M, Beddows I, Kitchen-Goosen SM, Roberts RD, Grohar PJ. Lurbinectedin inhibits the EWS-WT1 transcription factor in desmoplastic small round cell tumor. Mol Cancer Ther. 2022 Jun 2:molcanther.1003.2021. doi: 10.1158/1535-7163.MCT-21-1003. Epub ahead of print. PMID: 35657345.
Flores G, Grohar PJ. One oncogene, several vulnerabilities: EWS/FLI targeted therapies for Ewing sarcoma. J Bone Oncol. 2021 Dec 1;31:100404. doi: 10.1016/j.jbo.2021.100404. PMID: 34976713; PMCID: PMC8686064
Chasse MH, Johnson BK, Boguslawski EA, Sorensen KM, Rosien JE, Kang MH, Reynolds CP, Heo L, Madaj ZB, Beddows I, Foxa GE, Kitchen-Goosen SM, Williams BO, Triche TJ, Jr., Grohar PJ. Mithramycin induces promoter reprogramming and differentiation of rhabdoid tumor. EMBO Mol Med. 2021;13(2):e12640. Epub 2020/12/18. doi: 10.15252/emmm.202012640. PubMed PMID: 33332735; PMCID: PMC7863405.
Gedminas JM, Chasse MH, McBrairty M, Beddows I, Kitchen-Goosen SM, Grohar PJ. Desmoplastic small round cell tumor is dependent on the EWS-WT1 transcription factor. Oncogenesis. 2020;9(4):41. Epub 2020/04/30. doi: 10.1038/s41389-020-0224-1. PubMed PMID: 32345977; PMCID: PMC7188842.
Flores G, Everett JH, Boguslawski EA, Oswald BM, Madaj ZB, Beddows I, Dikalov S, Adams M, Klumpp-Thomas CA, Kitchen-Goosen SM, Martin SE, Caplen NJ, Helman LJ, Grohar PJ. CDK9 Blockade Exploits Context-dependent Transcriptional Changes to Improve Activity and Limit Toxicity of Mithramycin for Ewing Sarcoma. Mol Cancer Ther. 2020;19(5):1183-96. Epub 2020/03/05. doi: 10.1158/1535-7163.Mct-19-0775. PubMed PMID: 32127464.
Harlow ML, Chasse MH, Boguslawski EA, Sorensen KM, Gedminas JM, Kitchen-Goosen SM, Rothbart SB, Taslim C, Lessnick SL, Peck AS, Madaj ZB, Bowman MJ, Grohar PJ. Trabectedin Inhibits EWS-FLI1 and Evicts SWI/SNF from Chromatin in a Schedule-dependent Manner. Clin Cancer Res. 2019;25(11):3417-29. Epub 2019/02/07. doi: 10.1158/1078-0432.Ccr-18-3511. PubMed PMID: 30723142; PMCID: PMC6594545.
Grohar PJ, Glod J, Peer CJ, Sissung TM, Arnaldez FI, Long L, Figg WD, Whitcomb P, Helman LJ, Widemann BC. A phase I/II trial and pharmacokinetic study of mithramycin in children and adults with refractory Ewing sarcoma and EWS-FLI1 fusion transcript. Cancer Chemother Pharmacol. 2017;80(3):645-52. Epub 2017/07/25. doi: 10.1007/s00280-017-3382-x. PubMed PMID: 28735378; PMCID: PMC6413860.
Harlow ML, Maloney N, Roland J, Guillen Navarro MJ, Easton MK, Kitchen-Goosen SM, Boguslawski EA, Madaj ZB, Johnson BK, Bowman MJ, D'Incalci M, Winn ME, Turner L, Hostetter G, Galmarini CM, Aviles PM, Grohar PJ. Lurbinectedin Inactivates the Ewing Sarcoma Oncoprotein EWS-FLI1 by Redistributing It within the Nucleus. Cancer Res. 2016;76(22):6657-68. Epub 2016/11/05. doi: 10.1158/0008-5472.Can-16-0568. PubMed PMID: 27697767; PMCID: PMC5567825.
Osgood CL, Tantawy MN, Maloney N, Madaj ZB, Peck A, Boguslawski E, Jess J, Buck J, Winn ME, Manning HC, Grohar PJ. (18)F-FLT Positron Emission Tomography (PET) is a Pharmacodynamic Marker for EWS-FLI1 Activity and Ewing Sarcoma. Sci Rep. 2016;6:33926. Epub 2016/09/28. doi: 10.1038/srep33926. PubMed PMID: 27671553; PMCID: PMC5037393.
Osgood CL, Maloney N, Kidd CG, Kitchen-Goosen S, Segars L, Gebregiorgis M, Woldemichael GM, He M, Sankar S, Lessnick SL, Kang M, Smith M, Turner L, Madaj ZB, Winn ME, Núñez LE, González-Sabín J, Helman LJ, Morís F, Grohar PJ. Identification of Mithramycin Analogues with Improved Targeting of the EWS-FLI1 Transcription Factor. Clin Cancer Res. 2016;22(16):4105-18. Epub 2016/03/17. doi: 10.1158/1078-0432.Ccr-15-2624. PubMed PMID: 26979396; PMCID: PMC4987166.